Course: AKTU B.Tech 2nd Year | Semester III
Course Code: BBT302
Branch: Biotechnology (BT)
Unit V Overview
Connect water quality, bioremediation and industrial microbes with immunity against the listed bacterial, protozoan and viral diseases. Study vaccine mechanisms, hypersensitivity and immunotherapy through labelled diagrams, genuine micrographs and answered examples.
Topics Covered
| Syllabus area | Pages |
|---|---|
| Domestic water and wastewater | 2-5 |
| Bioremediation | 5-6 |
| Microbes of industrial use | 6-7 |
| Bacterial disease immunity | 7-8 |
| Protozoan disease immunity | 8-9 |
| Viral disease immunity | 9-11 |
| Vaccines and immune protection | 11-13 |
| Hypersensitivity and immunotherapy | 13-17 |
| Solved problems and revision | 17-20 |
Learning Outcomes
- Explain water treatment and bioremediation.
- Relate industrial organisms to useful products.
- Compare immunity in all seven listed diseases.
- Explain vaccination and protective memory.
- Distinguish hypersensitivity and therapy mechanisms.
Included in These Notes
34 explained sections; 25 labelled illustrations and plots; 10 actual photographs; 10 solved problems; comparison tables; answered revision questions and a quick-reference sheet.
Study Approach
Separate the outcomes. Organic-load removal, pathogen control and safe reuse are different goals.
Locate the pathogen. Connect extracellular, intracellular and stage-specific targets with useful effectors.
Name the mechanism. Compare active and passive protection and the four hypersensitivity types.
Interpret the evidence. Use worked examples to distinguish a measured response from demonstrated benefit.
Key distinctions: clean appearance is not proof of safe water; binding is not always neutralisation; immunotherapy can restrain as well as enhance immunity. State the biological target, useful effect and limitation.
1. Unit V framework: applications and host protection
Microorganisms can contaminate water, recycle waste, manufacture useful products and cause infection. Immunology explains how the host recognises these organisms, limits their spread, remembers previous encounters and sometimes causes tissue damage. The outcome depends on the organism, its location and the response it stimulates.
This unit connects environmental and industrial microbiology with immunity against tuberculosis, typhoid, malaria, amoebiasis, HIV/AIDS, dengue and chikungunya. It then explains vaccines, hypersensitivity and immunotherapy. For a clear answer, name the organism or antigen, the affected compartment, the useful mechanism and its limitation. Important distinction: removing organic pollution is not the same as removing every pathogen, and detecting an immune response is not proof of complete protection.
Figure explanation: The framework connects water quality, useful microbial metabolism and host protection. The biological outcome being assessed changes with the setting.
2. Domestic water: microbial communities and contamination
Domestic water is water used for drinking, food preparation, washing and other household purposes. Its microorganisms may come from source water, soil, sewage intrusion, storage containers and distribution-pipe biofilms. Natural environmental organisms are not all pathogens, but faecal contamination can introduce enteric bacteria, viruses and protozoan cysts or oocysts.
Clear appearance, acceptable taste and lack of odour do not establish microbiological safety. Turbidity can shelter organisms from treatment and can indicate problems with source quality or filtration. Contamination may occur after treatment through leaking pipes or unsafe storage. A complete safety approach therefore considers the source, treatment barriers, distribution and point of use rather than judging only the water leaving the treatment plant.
3. Indicator organisms and interpretation of water quality
Testing for every possible waterborne pathogen in every sample is impractical. Indicators are used to assess contamination or treatment performance. Escherichia coli is a useful indicator of faecal contamination; total coliforms are a broader group and are not an identical measure of recent faecal input. A positive indicator result identifies a concern, not necessarily the exact pathogen responsible for disease.
Membrane filtration estimates colony-forming units from an appropriate filtered volume. Multiple-tube approaches estimate a most probable number statistically from a defined pattern of positive reactions. Counts depend on the method, sample volume and recovery conditions. A negative result in one sample does not prove that every virus or chlorine-tolerant protozoan is absent. The photographed pathogenic E. coli strain illustrates morphology, not the identity of every indicator isolate.
Figure explanation: A water sample undergoes method-specific recovery followed by estimation and interpretation. Detecting an indicator is evidence about that sample, not identification of every pathogen.
Figure explanation: The colourised SEM shows pathogenic E. coli O157:H7 morphology. It does not identify a generic water-indicator strain from appearance alone.
4. Drinking-water treatment as multiple barriers
A typical surface-water system combines coagulation/flocculation, sedimentation, filtration and disinfection. Coagulation destabilises particles; flocculation encourages larger aggregates; settling removes heavier flocs. Filtration reduces remaining particles and organisms through the selected medium or membrane. The exact combination depends on source quality and treatment design.
Disinfection inactivates susceptible organisms; it is not identical to physical removal or sterilisation. Organic matter, turbidity and organism resistance can affect performance. A disinfectant residual can help control some organisms during distribution, whereas UV treatment does not supply a lasting residual. Storage and distribution hygiene remain important. These notes explain the barrier principle rather than prescribe a universal chemical dose or contact time.
Figure explanation: The conceptual barriers include coagulation/flocculation, settling, filtration, disinfection and protected distribution. Source quality and storage also influence the final water.
5. Wastewater microbiology: loads, risks and treatment stages
Domestic wastewater contains organic matter, suspended solids, nutrients and microorganisms. Some microbes drive useful degradation, while pathogens and antimicrobial-resistance determinants can also be present. Wastewater treatment manages pollution and health risks; it does not simply encourage the growth of a single “good bacterium”.
Preliminary operations remove coarse material and grit. Primary sedimentation removes settleable solids. Secondary biological treatment converts biodegradable material into microbial biomass, gases and other products, followed by solids separation. Further nutrient removal, polishing and disinfection depend on the intended discharge or reuse requirements. Sludge requires its own treatment and management. A biologically treated effluent should not automatically be described as drinking water.
Figure explanation: Primary settling, biological treatment and final solids separation address different wastewater components. Sludge management and further treatment remain distinct requirements.
6. Activated sludge: flocs, aeration and sludge return
Activated sludge is a suspended-growth biological process. Wastewater mixes with microbial flocs in an aerated basin. Heterotrophic microorganisms use biodegradable organic material; bacteria and other community members contribute to floc structure, while protozoa can graze on dispersed cells. Oxygen delivery and suitable operating conditions support the intended activity.
A secondary clarifier separates settleable biological solids from the treated liquid. Part of the settled sludge returns to maintain biomass; excess sludge is removed for separate management. Return sludge is not fresh untreated sewage. Poor settling or changes in microbial community can impair effluent quality. Biological oxidation and physical clarification are complementary: converting dissolved material into biomass does not remove that biomass until separation occurs.
Figure explanation: The activated-sludge model connects aeration and microbial flocs to a clarifier. Settled sludge returns to the biological stage, while excess sludge leaves for separate treatment.
7. Attached growth, anaerobic digestion and nutrient cycling
In attached-growth processes, microbes form biofilms on support surfaces. A trickling filter passes wastewater over a biologically active medium; it is not merely a sieve. Anaerobic digestion instead stabilises suitable organic material without free oxygen through linked hydrolysis, fermentation, acetogenesis and methanogenesis. Methanogenic archaea produce methane; a mixed community supplies their substrates.
Nitrogen removal also requires distinct transformations. Nitrification oxidises ammonium to nitrite and nitrate, usually in an oxygenated setting. Denitrification can reduce nitrate toward nitrogen gas under suitable anoxic conditions. Anoxic here means little free oxygen while nitrate can serve as an electron acceptor; it is not the same process as methanogenesis. Process conditions select communities and determine which transformation dominates.
Figure explanation: Nitrogen transformations require different conditions: nitrification oxidises ammonium through nitrite to nitrate under oxygen-associated conditions, while suitable anoxic nitrate reduction can return nitrogen to N2 gas.
8. BOD, COD and interpreting treatment performance
Biochemical oxygen demand estimates oxygen consumed through biological activity under stated test conditions. BOD5 is a five-day measurement under a specified method; it is not the dissolved oxygen remaining in a river. Chemical oxygen demand measures an oxidant-equivalent demand and can include material not readily biodegraded in a BOD test.
A reduction in BOD indicates removal or conversion of oxygen-demanding material, but does not by itself establish pathogen removal. Percentage removal=(influent concentration-effluent concentration)/influent concentration × 100 when the comparison is appropriate. Concentration reduction is not always equal to mass-load reduction if flow changes. Explain what was measured, its units and its limit before calling a treatment “effective”.
9. Bioremediation: biological transformation of pollutants
Bioremediation uses biological activity to reduce contamination or its harmful effects. Microbial enzymes can transform suitable organic pollutants; complete mineralisation converts organic carbon toward inorganic end products such as carbon dioxide under the relevant conditions. Partial transformation can instead produce intermediates, which may require further treatment.
Microbes do not destroy chemical elements. Metals can change oxidation state, become immobilised, bind to biomass or be separated, but are not metabolically converted into nothing. Pollutant availability, toxicity, oxygen or other electron acceptors, nutrients, pH and temperature influence remediation. Disappearance from water may represent transfer to solids rather than destruction. A meaningful assessment follows products and environmental risk as well as the parent contaminant.
Figure explanation: Microbial enzymes transform a pollutant into products that must be assessed for toxicity and persistence. Metals may be transformed or immobilised, but cannot be destroyed as elements.
10. Bioremediation strategies and practical limits
In situ treatment acts at the contaminated site; ex situ treatment handles removed material elsewhere. Biostimulation adjusts conditions to support useful resident organisms. Bioaugmentation adds selected organisms or consortia, but added cells must survive, access the pollutant and function under site conditions. Adding microbes is not automatically better than supporting an effective native community.
Examples include microbial hydrocarbon degradation, biological treatment of suitable industrial effluents and transformation or immobilisation of selected pollutants. Biosorption binds contaminants to biological material and is distinct from biodegradation. Monitoring compares contaminant levels, breakdown products, toxicity and relevant site conditions. The choice depends on the pollutant and setting; one organism or method cannot clean every contaminated environment.
| Term | What changes |
|---|---|
| Biostimulation | Conditions for useful resident organisms |
| Bioaugmentation | Introduction of selected biological agents |
| Biodegradation | Chemical structure of a degradable compound |
| Biosorption | Association with biological surfaces |
| Mineralisation | Organic material reaches inorganic end products |
11. Industrial microbes: organisms, products and functions
Selected microbial strains produce foods, fuels, organic acids, enzymes, antibiotics and recombinant products. Useful traits include stable production, suitable substrate use, product yield and predictable behaviour. A species name alone does not guarantee industrial performance or safe use: strain characteristics and quality control matter.
Yeast fermentation converts sugars into ethanol and carbon dioxide in a familiar model. Lactic-acid bacteria contribute to fermented foods; selected filamentous fungi produce enzymes or organic acids. Industrial antibiotics and recombinant proteins require specialised production and purification. The table gives representative associations, not a claim that every strain of each organism makes every product. Modern names and improved production strains can differ from older textbook examples.
Figure explanation: The archived micrograph illustrates Saccharomyces cerevisiae yeast. Industrial usefulness depends on the selected strain and process, not merely recognition of yeast morphology.
| Representative organism | Typical industrial association |
|---|---|
| Saccharomyces cerevisiae | Baking, brewing and ethanol production |
| Lactic-acid bacteria | Fermented foods and lactic acid |
| Aspergillus niger | Citric acid and selected enzymes |
| Penicillium production strains | Penicillin manufacture |
| Streptomyces species | Diverse antibiotics and metabolites |
| Selected E. coli or yeast hosts | Recombinant protein production |
12. From a bioreactor to a purified product
A production system links a selected organism and feedstock with a controlled vessel. Depending on the process, mixing, gas exchange, temperature, pH and foam control help maintain useful production conditions. Sensors measure conditions; they do not themselves guarantee a high product yield. An aerobic process needs suitable oxygen transfer, while other processes use different gas requirements.
Downstream processing separates the product from cells, medium components and unwanted substances. Extracellular products are recovered from the surrounding liquid; intracellular products require an appropriate release and recovery stage. Concentration, purification and formulation follow the product’s properties. Quality checks address identity, activity and relevant contaminants. Industrial production is therefore more than growing a large amount of biomass.
Figure explanation: The conceptual vessel labels mixing, sensors, gas supply where required, and product recovery/purification. Controlled production and downstream recovery form connected parts of a process.
13. Immunity against infection: location determines the response
Barriers and innate recognition respond early, while adaptive B- and T-cell responses provide antigen-specific mechanisms and memory. Antibodies can neutralise extracellular particles, block attachment or recruit effectors. Intracellular infection often requires infected-cell recognition or activation of phagocytes, rather than assuming antibody can enter every infected compartment.
Protective immunity and immunopathology can occur together. A response may limit spread yet also contribute to inflammation and tissue damage. Sterilising immunity prevents establishment of infection; protection from severe disease can occur even when infection remains possible. For each disease below, connect transmission and organism location with the major defence and a realistic limitation. A positive antibody result is not a universal certificate of resistance to reinfection.
Figure explanation: Antibodies can act on extracellular targets, whereas infected-cell targets need cellular effectors and coordination. Location helps determine which immune mechanisms are useful.
14. Tuberculosis: macrophages, T cells and granulomas
Tuberculosis is caused mainly by Mycobacterium tuberculosis and commonly follows inhalation of infectious aerosols. Bacilli encounter alveolar macrophages and can persist within a modified intracellular environment. Innate recognition initiates recruitment, but effective containment depends strongly on cellular immunity.
Th1-associated responses, including IFN-γ-mediated macrophage activation, and TNF-supported organisation help contain infection. Granulomas organise infected and immune cells; they can restrict spread without sterilising every focus. Immune-mediated inflammation also contributes to injury. Latent infection is distinct from active disease, and immunosuppression can disrupt containment. BCG helps protect children against severe forms of TB, but does not uniformly prevent adult pulmonary infection. A skin test or IGRA measures an immune response and cannot alone distinguish latent infection from active TB.
Figure explanation: A macrophage-rich granuloma region is surrounded by a lymphocyte rim. T-cell signals support containment, but organised containment does not establish sterilising clearance.
Figure explanation: The colourised SEM shows Mycobacterium tuberculosis bacilli. Macrophage activation and T-cell-mediated containment are explained by the adjacent model, not directly visible in the organism image.
15. Typhoid: intestinal entry and systemic infection
Typhoid fever is caused by Salmonella enterica serovar Typhi, commonly called Salmonella Typhi. Infection usually follows ingestion of contaminated food or water. The organism crosses the intestinal barrier, interacts with phagocytic cells and can disseminate systemically. It should not be confused with every form of non-typhoidal salmonellosis.
Mucosal barriers, innate mechanisms, antibodies and cellular responses all contribute to defence. The Vi capsule helps the organism resist aspects of host recognition. Vi-containing vaccines induce targeted responses; conjugating polysaccharide to a carrier protein improves T-cell-dependent help and memory compared with a plain polysaccharide response. Vaccination does not replace sanitation. A single historical agglutination titre is not definitive proof of current typhoid, and infection can leave a carrier state rather than guaranteed sterilising immunity.
Figure explanation: Crossing the intestinal barrier permits systemic dissemination in the typhoid model. Mucosal, antibody and cellular mechanisms cooperate at different stages.
Figure explanation: The archived fluorescent-antibody comparison illustrates labelled Salmonella Typhi. Fluorescent appearance is an assay-associated signal rather than a direct image of protective immunity.
16. Malaria: stage-specific immunity and incomplete protection
Malaria is caused by Plasmodium parasites transmitted by infected female Anopheles mosquitoes. Sporozoites first reach the liver; released merozoites invade erythrocytes and initiate repeated blood-stage cycles. The asexual blood stages are central to disease. Some parasites form gametocytes that can be taken up by mosquitoes.
Antibodies can act against extracellular stages and infected-cell-associated targets, while T-cell mechanisms are important for liver-stage and immune coordination. Mature erythrocytes lack conventional MHC class I, so do not describe ordinary CD8 recognition of an infected red cell as if it were a nucleated liver cell. Parasite variation and multiple stages complicate protection. Repeated exposure can produce partial clinical immunity without complete prevention of infection. Malaria vaccines can target defined stages and reduce disease risk; they do not replace mosquito control.
Figure explanation: The malaria model distinguishes sporozoite-associated liver infection, asexual blood stages and gametocytes taken up by mosquitoes. Immune protection is stage-specific, and red cells lack conventional MHC I.
Figure explanation: The blood film shows a Plasmodium falciparum microgametocyte. This sexual stage differs from the asexual blood stages responsible for the principal clinical illness.
17. Amoebiasis: mucosal defence and tissue invasion
Amoebiasis, also written amebiasis, is caused by pathogenic Entamoeba histolytica. Infection commonly follows ingestion of mature cysts from faecally contaminated material. Excystation releases trophozoites that colonise the large intestine; some invade mucosa and can spread to extraintestinal sites such as the liver.
The mucus barrier, innate responses and mucosal antibodies, including secretory IgA against adhesion-associated targets, contribute to protection. Cell-mediated mechanisms also participate, while inflammation and parasite-mediated injury can damage tissue. Protection is not invariably complete or lifelong. Morphologically similar Entamoeba species complicate identification; ordinary microscopy alone may not reliably separate them. The cyst is important for environmental transmission, whereas trophozoites are the active colonising and invasive stage.
Figure explanation: Mature cysts support transmission, while trophozoites colonise and may invade mucosa, with possible spread to the liver. Mucus, IgA and cellular responses help limit invasion.
Figure explanation: The trichrome-stained image highlights Entamoeba histolytica trophozoite morphology. An immune response is not directly visible in the stain.
18. HIV and AIDS: infection of the immune system
Human immunodeficiency virus infects susceptible cells through CD4 with an appropriate coreceptor, commonly CCR5 or CXCR4. Viral RNA is reverse-transcribed, and proviral DNA can integrate into a host-cell genome. Persistent reservoirs and viral variation help explain why an immune response does not routinely eradicate infection.
CD8 responses and antibodies can constrain parts of infection, but progressive damage to CD4 T-cell function undermines immune coordination. AIDS is an advanced syndrome associated with severe immune impairment; HIV infection and AIDS are not interchangeable labels for every stage.
Antiretroviral therapy suppresses replication and supports immune recovery but is not simply a vaccine or a direct immune-memory booster. Opportunistic infections arise because defence is impaired, not because HIV transforms into each opportunistic organism.
Figure explanation: HIV entry involves CD4 and a coreceptor, followed by reverse transcription and integration. Persistent infection undermines CD4-associated immune coordination and increases opportunistic disease risk.
Figure explanation: The colourised thin-section TEM shows HIV virions. Their appearance alone does not measure CD4-cell function or immune impairment.
19. Dengue: serotypes, neutralisation and enhancement
Dengue viruses are transmitted mainly by infected Aedes mosquitoes. Four major serotypes are recognised. Innate antiviral mechanisms and adaptive responses develop during infection; effective neutralising antibodies can prevent or reduce successful infection by compatible viral targets. Immunity after one infection is strongest against that same serotype rather than universally equivalent against all four.
During a later heterologous infection, some cross-reactive antibodies may bind without adequately neutralising. Fc-receptor-mediated uptake can contribute to antibody-dependent enhancement under suitable conditions. Severe dengue is multifactorial: prior infection does not make severe disease inevitable, and not every antibody enhances infection. Vascular leakage and immune dysregulation are important disease features. Vaccine benefit and eligibility depend on product and population; a generic rule that every person should receive the same dengue vaccine is inaccurate.
Figure explanation: Antibody binding can lead to effective dengue neutralisation or, in an inadequate-neutralisation context, Fc-associated uptake. Binding and neutralisation are therefore distinct outcomes.
Figure explanation: The TEM shows dengue virus particles in tissue. It does not directly demonstrate antibody-dependent enhancement or identify the protective quality of an antibody response.
20. Chikungunya: antiviral protection and persistent inflammation
Chikungunya is an alphavirus infection spread mainly by infected Aedes mosquitoes. Fever and prominent joint pain are characteristic clinical features, with symptoms that can overlap with other infections. It is a distinct virus from dengue despite shared vector groups and overlapping geographical distribution.
Type I interferon-associated responses contribute to early antiviral defence. Neutralising antibodies and cellular responses help control infection, and recovery commonly produces substantial protection against subsequent infection. Persistent joint symptoms in some people involve ongoing inflammatory and tissue-associated mechanisms; they do not automatically prove continuous high-level viraemia. Chikungunya vaccines have entered use in some jurisdictions, but availability and recommendations vary. Mosquito control remains relevant to both chikungunya and dengue.
Figure explanation: Antiviral control and joint inflammation are distinct outcomes in chikungunya. Persistent joint symptoms alone do not prove continuing viraemia.
Figure explanation: The digitally colourised TEM shows chikungunya particles with dense cores and surrounding envelopes. The image illustrates virion structure rather than the cause of persistent joint symptoms.
21. Comparing the seven disease-immunity patterns
A high-scoring comparison names the pathogen, its relevant location and the central immune challenge. Avoid replacing all seven mechanisms with “antibodies kill germs”. Protective responses cooperate, and several pathogens exploit an intracellular phase or antigenic variation.
Do not infer disease identity from fever alone or interpret a micrograph as a complete patient diagnosis. The table summarises mechanisms for revision. Antimicrobial therapy acts on pathogens, vaccination prepares immunity, and immunotherapy modifies or supplies immune mechanisms; these categories can support one another but are not synonyms.
| Disease | Immune emphasis / main limitation |
|---|---|
| Tuberculosis | Macrophage-T-cell cooperation; containment can fail |
| Typhoid | Mucosal, humoral and cellular defence; systemic spread |
| Malaria | Stage-specific responses; incomplete clinical immunity |
| Amoebiasis | Mucosal barriers and responses; invasive escape |
| HIV/AIDS | Persistent virus damages CD4 coordination |
| Dengue | Serotype-dependent protection; enhancement can occur |
| Chikungunya | Antiviral responses; joint inflammation may persist |
22. Active and passive immunity
Active immunity results from the individual’s own adaptive response after infection or vaccination. It takes time to develop and can generate memory. Passive immunity supplies preformed immune components, usually antibodies, and can act promptly but does not by itself establish the recipient’s own corresponding memory population.
Natural passive examples include maternal IgG transfer across the placenta and secretory antibodies in milk. Administered immunoglobulin or selected monoclonal antibodies are artificial passive approaches. Protection wanes as transferred antibodies are removed. Active and passive measures can be combined for particular indications, but their timing and compatibility are method-dependent. “Artificial” describes how protection is acquired, not whether it is ineffective or biologically unreal.
Figure explanation: Active protection follows an individual’s own response to infection or vaccination and can generate memory. Passive protection supplies antibody that wanes as it is removed.
23. Vaccine platforms and representative examples
Vaccines expose the immune system to an appropriate antigenic stimulus without requiring the full natural disease course. Live-attenuated, inactivated, subunit, conjugate, toxoid, viral-vector and nucleic-acid platforms differ in how antigen is supplied or made. A toxoid targets a toxin-mediated disease mechanism; it is not an antibiotic that kills the organism.
Conjugate vaccines link a polysaccharide to a carrier to recruit protein-specific T-cell help. In mRNA vaccination, delivered RNA supports antigen production and is not designed to integrate into the host genome. Viral vectors deliver a genetic instruction through a modified vector. Platforms differ in storage, immune responses and use restrictions. Product selection cannot be decided from platform name alone.
| Platform | Teaching example / principle |
|---|---|
| Live attenuated | BCG: weakened organism stimulates responses |
| Inactivated | Non-replicating whole-organism preparation |
| Subunit | Selected antigen rather than whole pathogen |
| Conjugate | Typhoid Vi antigen linked to carrier protein |
| Toxoid | Inactivated toxin antigen, e.g. tetanus toxoid |
| Vector / nucleic acid | Antigen instruction delivered for host expression |
24. How vaccination creates memory
Antigen capture and innate signals support antigen presentation and lymphocyte activation. Suitable helper responses coordinate B-cell expansion, antibody production and germinal-centre selection. Depending on platform and context, cellular responses also develop. Memory cells and long-lived plasma cells have different roles: one supports rapid recall; the other can sustain antibody secretion.
A booster re-exposes a prepared immune system and can strengthen or prolong a response. Adjuvants improve suitable immune stimulation; they are not the same as the protective antigen or an antimicrobial drug. Not every vaccine produces identical lifelong immunity, and antibody concentration is not the sole possible correlate of protection. Immune maturation, age, health and prior exposure affect responses.
Figure explanation: Antigen presentation activates selected lymphocytes and supports memory populations and long-lived plasma cells. Memory cells and continuing antibody secretion are related but different outcomes.
25. Protection, efficacy and population effects
Vaccine efficacy compares specified outcomes between vaccinated and control groups under a study design. In a simplified risk comparison, efficacy=(1-risk in vaccinated/risk in unvaccinated) × 100. Preventing infection, symptomatic illness and severe disease are different endpoints, so the percentage needs its outcome and follow-up context.
Reduced transmission can protect susceptible people indirectly when vaccination sufficiently interrupts spread. A simple homogeneous model gives a herd-immunity threshold of 1-1/R0, but real coverage needs depend on vaccine effectiveness against transmission, waning and population mixing. The formula is not a universal target for every vaccine or disease. Product authorisation and schedules change; the durable lesson is to distinguish immune mechanism, individual benefit and population-level effect.
Figure explanation: The illustrative response plot shows a faster and stronger recall response after re-exposure. Response kinetics are conceptual and do not alone establish clinical vaccine efficacy.
26. Hypersensitivity: immune mechanisms that cause injury
Hypersensitivity is tissue injury caused by an inappropriate or excessive immune response in a sensitised or otherwise susceptible setting. The Gell-Coombs framework groups mechanisms into types I, II, III and IV. It is a useful classification, although real diseases may involve more than one mechanism.
Types I, II and III involve antibodies in different ways; type IV is mediated by T cells. Rapid versus delayed timing helps interpretation but cannot replace the mechanism. Hypersensitivity is not identical to autoimmunity: an allergen may be external, while autoimmunity concerns self targets. Immunodeficiency means impaired defence and is a different concept again.
| Type | Main mechanism | Illustrative example |
|---|---|---|
| I | IgE, mast cells and mediators | Allergic rhinitis; some anaphylaxis |
| II | Antibody against fixed cell/tissue targets | Incompatible red-cell transfusion |
| III | Deposited soluble immune complexes | Serum sickness; Arthus reaction |
| IV | T-cell-mediated inflammation or injury | Contact dermatitis; tuberculin reaction |
27. Type I: sensitisation, IgE and mast-cell activation
During sensitisation, a type 2-associated response supports IgE production against an allergen. IgE binds high-affinity Fc receptors on mast cells and basophils. On later exposure, a suitable multivalent allergen can cross-link receptor-bound IgE and trigger mediator release.
Histamine and lipid mediators contribute to vascular and smooth-muscle effects; later recruitment can sustain inflammation. Local effects include rhinitis or selected asthma mechanisms; systemic activation can produce anaphylaxis. Not all asthma is IgE-mediated, and food intolerance is not synonymous with immune food allergy. The diagram separates sensitisation from re-exposure so that IgE binding alone is not confused with full degranulation.
Figure explanation: An allergen bridges surface-bound IgE on a sensitised mast cell, triggering mediator release. The drawing distinguishes sensitisation-associated IgE from the subsequent triggering encounter.
Figure explanation: The SEM shows pollen grains with varied surfaces. Pollen allergens can trigger IgE-mediated reactions in sensitised individuals; shape alone does not establish sensitisation.
28. Type II: antibodies against fixed targets
Type II reactions involve antibodies, commonly IgG or IgM, directed against antigens associated with cells or tissue structures. Complement recruitment, Fc-receptor-dependent cellular action or interference with a receptor can produce injury or abnormal function. The antigen is attached to a target rather than primarily circulating as a soluble immune complex.
In an incompatible red-cell transfusion example, antibody recognition can trigger destructive effector mechanisms. Some receptor-targeting antibodies instead stimulate or block a function without directly lysing the cell. Thus “cytotoxic” is useful shorthand for some type II reactions, not a complete definition of every example. Name the target and the effector instead of assuming IgE and mast-cell degranulation explain every antibody-mediated disorder.
Figure explanation: Type II antibodies bind fixed cell-associated targets and recruit effectors. Depending on the target, the outcome can be cell injury or altered receptor function.
29. Type III: immune-complex deposition and inflammation
Soluble antigens and antibodies form complexes that are normally handled by clearance mechanisms. When formation, persistence and deposition exceed effective handling, complexes can accumulate in tissues and activate complement and inflammatory cells. Neutrophil-associated mediators can then injure nearby tissue.
Serum sickness is a systemic teaching example; an Arthus reaction is a local example. Antigen-antibody binding itself is normal biology, so not every immune complex causes disease. Complex characteristics, location and clearance matter. Distinguish type III deposition of soluble complexes from type II recognition of a fixed tissue or cell-associated antigen. Both can recruit complement, but the starting arrangement differs.
Figure explanation: Deposited soluble immune complexes recruit complement and inflammatory cells, which can injure neighbouring tissue. This deposited-complex mechanism defines the type III model.
30. Type IV: T cells and delayed tissue injury
Type IV reactions are mediated by antigen-specific T cells rather than a required antibody effector. Re-exposure can recruit cytokine-producing helper cells and activated macrophages or involve cytotoxic T-cell injury. Many classic reactions develop over roughly 48-72 hours, with timing varying by mechanism and context.
Contact dermatitis to suitable small chemical-associated antigens and the tuberculin skin response are familiar examples. A positive tuberculin reaction demonstrates sensitisation and requires clinical interpretation; it does not by itself establish active tuberculosis. Unlike immediate IgE-mediated degranulation, a delayed response depends on cellular recruitment and activation. The same broad cellular machinery can be protective against infection in one context and damaging in another.
Figure explanation: Sensitised T cells activate cellular effectors and cytokine-mediated tissue injury. Helper-cell and cytotoxic mechanisms vary with the type IV example.
31. Immunotherapy: supplying, redirecting or restraining immunity
Immunotherapy uses immune components or modifies immune mechanisms for a therapeutic purpose. Some approaches enhance recognition or effector activity; others block harmful inflammation or promote controlled tolerance. It is therefore inaccurate to define all immunotherapy as a nonspecific increase in immunity.
Examples include therapeutic antibodies, checkpoint blockade, selected adoptive-cell treatments, cytokine-related interventions and allergen-specific immunotherapy. The target, mechanism and indication determine the expected benefit. An antibacterial drug that inhibits a bacterial enzyme is not automatically immunotherapy merely because infection improves. Therapeutic vaccination against an existing target also differs in purpose from routine prophylactic vaccination.
| Approach | Mechanistic goal |
|---|---|
| Preformed specific antibody | Supply binding or neutralising activity |
| Checkpoint blockade | Release selected inhibitory signals |
| Adoptive immune cells | Supply or redirect cellular effectors |
| Cytokine targeting | Modify a signalling pathway |
| Allergen immunotherapy | Promote a less harmful response to a defined allergen |
32. Therapeutic antibodies and immune checkpoints
A therapeutic monoclonal antibody can neutralise a target, block a receptor or ligand, mark cells for recruited effectors, or act as part of another delivery system. Mechanism depends on the molecule; not every therapeutic antibody kills cells through complement. Target expression and access influence response.
Checkpoint pathways such as PD-1/PD-L1 normally restrain immune activity. Blocking an appropriate checkpoint can restore or strengthen anti-tumour T-cell action in selected settings. Removing restraint can also cause immune-mediated injury, so more immune activity is not automatically better. A checkpoint inhibitor does not generally provide a new antigen receptor or directly rewrite every T cell’s specificity.
Figure explanation: A blocking antibody interrupts an inhibitory checkpoint interaction, permitting stronger T-cell action. The outcome depends on the target, context and remaining immune functions.
33. Adoptive cells and allergen-specific immunotherapy
Adoptive-cell approaches transfer selected or modified immune cells. A CAR-T design supplies an engineered recognition receptor to T cells; some CARs recognise suitable surface targets without the conventional peptide-MHC binding requirement of a TCR. This does not mean every cancer has a suitable target or that all cellular therapies use the same design.
Allergen-specific immunotherapy instead aims to reduce a harmful response to a defined allergen through supervised repeated exposure and immune regulation. Changes can include regulatory responses and altered antibody patterns rather than a simple switch that deletes all IgE. It is not equivalent to unsupervised allergen exposure or a universal treatment for every allergy. These examples show two different goals: redirect useful effectors versus restrain an inappropriate response.
Figure explanation: An engineered CAR recognition domain redirects a T cell toward a surface-target-bearing cell. Surface recognition differs from conventional peptide–MHC recognition by a T-cell receptor.
34. Integrated revision: useful microbes and controlled immunity
Water management, industrial production and host defence all depend on selecting the right biological function for the right setting. Wastewater degradation requires a community and process conditions; industrial manufacture requires product recovery; protection against an intracellular pathogen needs more than a generic antibody statement.
For an exam answer, begin with the definition, follow the labelled mechanism, give one appropriate example and state one limitation. Compare BOD removal with disinfection, biostimulation with bioaugmentation, active with passive immunity, and the four hypersensitivity mechanisms. Finish by explaining how a therapeutic intervention changes the specific process rather than claiming it improves every immune function.
WORKED QUESTIONS: APPLICATIONS AND INTERPRETATION
Use the stated teaching assumptions, units and biological context. Each example includes its solution and the limit of the conclusion.
Worked problem 5.1: Indicator concentration from a filtered volume
Question: A suitable method recovers 18 colonies from 50 mL. Estimate CFU per 100 mL, assuming each counted colony represents one recovered CFU.
Step 1: Volume factor=100/50=2.
Step 2: Estimated concentration=18 × 2=36 CFU per 100 mL.
Step 3: The estimate concerns the specified recoverable indicator, not every organism in the water.
Answer: 36 CFU/100 mL.
Check: Clumping and method recovery affect CFU; do not replace CFU with an exact cell count.
Worked problem 5.2: BOD removal
Question: Influent BOD is 240 mg/L and effluent BOD is 24 mg/L at equal flow. Calculate percentage removal.
Step 1: Concentration reduction=240-24=216 mg/L.
Step 2: Fraction removed=216/240=0.90.
Step 3: Percentage removal=0.90 × 100=90%.
Answer: 90% BOD removal under the stated comparison.
Check: This number does not establish 90% pathogen inactivation or drinking-water safety.
Worked problem 5.3: Concentration versus mass load
Question: A stream of 100 m³/day contains 200 mg/L of a measured pollutant. Find the daily load.
Step 1: 100 m³/day=100000 L/day.
Step 2: Mass=100000 × 200=20000000 mg/day.
Step 3: Divide by 1000000 mg/kg: load=20 kg/day.
Answer: 20 kg/day.
Check: A concentration change must be combined with flow before claiming a change in total discharged mass.
Worked problem 5.4: Biostimulation or bioaugmentation?
Question: A site already contains organisms capable of degrading a pollutant. Conditions are adjusted to support them, with no new organisms added. Name the approach.
Step 1: The useful organisms are already resident.
Step 2: The intervention changes the environment rather than introduces a selected culture.
Step 3: This matches biostimulation.
Answer: Biostimulation.
Check: If a selected culture were introduced, that would describe bioaugmentation; successful remediation would still need evidence.
Worked problem 5.5: Product recovery
Question: An industrial protein is retained inside the production cells. Can removing the cells and discarding them yield the product from the clear liquid alone?
Step 1: The specified product location is intracellular.
Step 2: Discarding cells discards much of the desired material in this model.
Step 3: Recovery needs a suitable cell-handling and product-release stage before purification.
Answer: No. The recovery route must account for intracellular location.
Check: Extracellular and intracellular products require different initial downstream choices.
Worked problem 5.6: Why malaria stages need different explanations
Question: A student says CD8 cells routinely recognise parasite peptides on class I molecules of mature infected erythrocytes. Correct the statement.
Step 1: Mature erythrocytes do not express conventional MHC class I as nucleated cells do.
Step 2: Liver-stage infected cells can support conventional class I-associated recognition.
Step 3: Blood-stage defence relies on other coordinated mechanisms, including antibody-associated effects.
Answer: Do not apply the nucleated-cell CD8 recognition model directly to mature erythrocytes.
Check: Stage-specific immunity is not equivalent to saying T cells have no role in malaria.
Worked problem 5.7: A dengue binding result
Question: An antibody binds a heterologous dengue serotype in a test. Does this prove protection against that serotype?
Step 1: Binding and neutralisation are different measured properties.
Step 2: A cross-reactive antibody may neutralise well, poorly or not adequately under the tested conditions.
Step 3: Enhancement can occur in suitable contexts; it is not inevitable from binding alone.
Answer: No. Protective function requires evidence beyond binding.
Check: Neither universal protection nor inevitable severe disease follows from this single observation.
Worked problem 5.8: Vaccine efficacy with a defined endpoint
Question: In equal hypothetical groups, symptomatic disease occurs in 20 of 1000 vaccinated participants and 100 of 1000 controls. Estimate efficacy against that endpoint.
Step 1: Vaccinated risk=20/1000=0.02; control risk=100/1000=0.10.
Step 2: Relative risk=0.02/0.10=0.20.
Step 3: Efficacy=(1-0.20) × 100=80%.
Answer: 80% efficacy against symptomatic disease in this simplified comparison.
Check: This is not automatically efficacy against all infection, transmission or severe disease; precision also requires uncertainty estimates.
Worked problem 5.9: Separating hypersensitivity mechanisms
Question: One reaction involves antibody against a red-cell surface; another involves deposited soluble complexes. Which types fit?
Step 1: Antibody against a fixed cell-associated antigen fits the type II framework.
Step 2: Deposited soluble antigen-antibody complexes fit the type III framework.
Step 3: Both can recruit complement, so complement alone does not distinguish them.
Answer: Fixed red-cell target: type II. Deposited soluble complexes: type III.
Check: Type I uses IgE-associated mast-cell activation; type IV uses T-cell mechanisms.
Worked problem 5.10: Opposite goals within immunotherapy
Question: Checkpoint blockade increases selected anti-tumour immune activity, while allergen immunotherapy reduces a harmful response. Can both be immunotherapy?
Step 1: Immunotherapy is defined by therapeutic use or modification of immune mechanisms.
Step 2: It can enhance, redirect, supply or restrain a response.
Step 3: The two interventions have different targets and desired outcomes.
Answer: Yes. Immunotherapy does not mean indiscriminately boosting every immune function.
Check: Identify the target and mechanism before claiming a treatment will improve a particular response.
Quick Revision: Answers with Reasons
Does clear water establish microbial safety?
No. Pathogens may be present without visible turbidity, and contamination can occur during distribution or storage.
Why use an indicator organism?
It provides evidence about contamination or process performance when testing every possible pathogen is impractical.
Is biological treatment the same as disinfection?
No. Organic-load conversion and separation do not guarantee adequate pathogen inactivation.
Why return activated sludge?
It retains a useful biomass population in the treatment system; excess solids still require separate management.
What separates nitrification from denitrification?
Nitrification oxidises ammonium toward nitrate; denitrification reduces nitrate toward gaseous nitrogen under suitable conditions.
Can microbes destroy a metal element?
No. They can transform its chemical state, bind it or help immobilise or separate it.
How does biostimulation differ from bioaugmentation?
Biostimulation supports resident organisms by changing conditions; bioaugmentation introduces selected organisms.
Why is downstream processing necessary?
A useful product must be separated from cells and unwanted material, purified appropriately and checked for quality.
What is central to TB containment?
Macrophage-T-cell cooperation, including activating signals and organised granuloma responses; containment does not ensure sterilisation.
Why does a typhoid conjugate use a carrier?
The carrier supports T-cell-dependent help for the polysaccharide-associated response and improves memory characteristics.
Does malaria immunity always prevent reinfection?
No. Repeated exposure can produce partial protection against disease while infection remains possible.
Which amoebic stage supports environmental transmission?
Mature cysts are the important resistant transmission stage; trophozoites colonise and may invade tissues.
Are HIV infection and AIDS identical terms?
No. AIDS describes an advanced syndrome of severe immune impairment in the course of HIV infection.
Why are dengue serotypes important?
Protection against one serotype is not equivalent to uniform protection against all four, and cross-reactive responses have different functional effects.
Does persistent chikungunya joint pain prove viraemia?
No. Persistent inflammatory symptoms cannot alone establish continuing high-level virus in blood.
Does passive antibody create the recipient’s own memory?
Not by itself. It supplies a component of protection that wanes as the transferred antibody is removed.
Are memory cells and plasma cells interchangeable?
No. Memory cells support recall responses; long-lived plasma cells can sustain antibody secretion.
How do type II and III reactions differ?
Type II begins with antibody directed against fixed cell or tissue targets; type III centres on deposited soluble immune complexes.
Is type IV an IgE reaction?
No. It is T-cell-mediated and can recruit macrophages or involve cytotoxic-cell injury.
Is every immunotherapy an immune stimulant?
No. Depending on purpose, it can supply, redirect, enhance or restrain selected immune mechanisms.
QUICK REFERENCE: APPLICATIONS AND RELATIONS
| Concept | Revision relation / distinction |
|---|---|
| CFU scaling | CFU per target volume=count × target volume / tested volume, with method assumptions. |
| Removal | % removal=(Cin-Cout)/Cin × 100, for an appropriate comparison. |
| Mass load | Load (kg/day)=Q (m³/day) × C (mg/L) × 0.001. |
| Efficacy | VE=(1-risk vaccinated/risk control) × 100; state the endpoint. |
| Simple threshold | H=1-1/R0 in a homogeneous model with its assumptions; not a universal coverage rule. |
| Water treatment | Barrier removal + inactivation + protected delivery. |
| Bioremediation | Transformation is not automatically complete mineralisation or reduced toxicity. |
| Active / passive | Own response and possible memory / transferred component without own memory from transfer alone. |
| Type I | IgE-associated mast-cell activation and mediator release. |
| Type II | Antibody against fixed cell or tissue targets. |
| Type III | Deposited soluble immune complexes and inflammation. |
| Type IV | T-cell-mediated response and tissue injury. |
| Immunotherapy | A defined immune target and desired effect, with context-dependent limits. |